Thông tin chi tiết tài liệu

Quốc hội

Thủ tướng Chính phủ

Liên bộ

Danh sách các Bộ, Ngành

Click vào tìm kiếm

Danh sách các tỉnh & thành phố trực thuộc Trung ương

Chi tiết tài liệu

An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma

Tác giả: Berliner, Leonard; Lemke, Heinz U.

Chủ đề:

Chủ đề: Medicine; Hepatocellular Carcinoma

Nhà xuất bản: Springer

Năm xuất bản: 2015

Loại tài liệu: Book

Mô tả vật lý: 143 p.

Định danh: 978-3-319-12166-6

Ngôn ngữ: en

Liên kết: Advances in Predictive, Preventive and Personalised Medicine;Book 8

Đọc trực tuyến

The subject was approached with four interrelated tasks: (1) review of clinical practices relating to HCC; (2) propose an IT system relating to HCC, including clinical decision support and research needs; (3) determine how a clinical liver cancer center can contribute; and, (4) examine the enhancements and impact that the first three tasks will have on the management of HCC. An IT System for Personalized Medicine (ITS-PM) for HCC will provide the means to identify and determine the relative value of the wide number of variables, including clinical assessment of the patient -- functional status, liver function, degree of cirrhosis, and comorbidities; tumor biology, at a molecular, genetic and anatomic level; tumor burden and individual patient response; medical and operative treatments and their outcomes

About The Editor
Cover
Advances in Predictive, Preventive and Personalised Medicine
Title pages
Copyright
What This Book Series is About
- Advanced Healthcare Tailored to the Person: What is Beyond the Issue?
- Current Healthcare: What is Behind the issue?
- Why Integrative Medical Approach by PPPM as the Medicine of the Future?
Foreword
Preface
Contents
Contributors
List of Abbreviations
Introduction
- 1.1 Introduction
  - 1.1.1 Predictive, Preventive and Personalized Medicine
  - 1.1.2 PPPM and Evidence-Based Medicine
  - 1.1.3 Personalized Medicine, Biomarkers, and Information Technology
  - 1.1.4 Clinical Liver Tumor Treatment Program as Use-Case
- Conclusion
- References
The Digital Patient Model and Model Guided Therapy
- 2.1 Introduction
  - 2.1.1 Therapy Imaging and Model Management System
  - 2.1.2 Digital Patient Model
  - 2.1.3 Multi-Entity Bayesian Network (MEBN)
  - 2.1.4 UnBBayes
- Conclusion
- References
Hepatocellular Carcinoma and Patient Assessment
- 3.1 Introduction
  - 3.1.1 Pathology of Hepatocellular Carcinoma
  - 3.1.2 Clinical Liver Cancer Center
  - 3.1.3 Screening for Hepatocellular Carcinoma
  - 3.1.4 Diagnosis of Hepatocellular Carcinoma
    - 3.1.4.1 Liver Lesions > 2 cm in Diameter
    - 3.1.4.2 Liver Lesions 1–2 cm in Diameter
    - 3.1.4.3 Liver Lesions < 1 cm in Diameter
  - 3.1.5 Staging of Hepatocellular Carcinoma
  - 3.1.6 Functional Assessment
  - 3.1.7 Construction of Database
- Conclusion
- References
Imaging in Hepatocellular Carcinoma: Radiologic Assessment
- 4.1 Introduction
  - 4.1.1 Diagnosis of HCC
  - 4.1.2 New Diagnostic Tools
    - 4.1.2.1 Diffusion-Weighted Imaging (DWI)
    - 4.1.2.2 Hepatospecific Contrast Agents for MR
  - 4.1.3 Therapeutic Algorithm and Treatment Planning
    - 4.1.3.1 Very Early Stage
    - 4.1.3.2 Early Stage
    - 4.1.3.3 Intermediate Stage
    - 4.1.3.4 Advanced Stage
  - 4.1.4 Post-Treatment Evaluation
  - 4.1.5 Electronic Medical Records and Radiological Data
- Conclusion
- References
Imaging in Hepatocellular Carcinoma: PET/CT
- 5.1 Introduction
  - 5.1.1 Pharmacology
  - 5.1.2 Role of PET Imaging in Oncology
    - 5.1.2.1 Diagnosis
    - 5.1.2.2 Response to Treatment
  - 5.1.3 PET/CT in Guiding Ablation Therapies to the Liver
    - 5.1.3.1 Metastatic Liver Disease
    - 5.1.3.2 Hepatocellular Cancer
    - 5.1.3.3 Pre-Operative Evaluation
    - 5.1.3.4 Response to Treatment
- Conclusion
- References
Personalized Chemotherapy for Hepatocellular Carcinoma
- 6.1 Introduction
  - 6.1.5 Personalized Recommendations—Chemotherapy for Hepatocellular Carcinoma
  - 6.1.1 Preventative Risk Factors in Hepatocellular Carcinoma
  - 6.1.2 Discussion of Molecular/Genetic Etiology of HCC
  - 6.1.3 Staging and Personalized Patient Evaluation in Hepatocellular Carcinoma
  - 6.1.4 Targeted and Predictive Treatment in Hepatocellular Carcinoma
    - 6.1.4.1 Monotherapy: Doxorubicin
    - 6.1.4.2 Molecular Targeted Therapy: Sorafenib
- Conclusion
- References
Surgical Treatment for Hepatocellular Carcinoma
- 7.1 Introduction
  - 7.1.1 Surgical Resection
  - 7.1.2 Surgical Resection Techniques
  - 7.1.3 Liver Transplantation
  - 7.1.4 Down-staging and Bridging Therapies
  - 7.1.5 Living vs. Deceased Liver Donor
- Conclusion
- References
Minimally Invasive Therapies for Hepatocellular Cancer: Ablation Technologies
- 8.1 Introduction
  - 8.1.1 Introduction to Tumor Ablation
  - 8.1.2 Forms of Ablation
  - 8.1.3 Radiofrequency Ablation
  - 8.1.4 Electromagnetic Radiation
    - 8.1.4.1 Laser Therapy
    - 8.1.4.2 Microwave Ablation
  - 8.1.5 Cryoablation
  - 8.1.6 Irreversible Electroporation
- Conclusion
Minimally Invasive Therapies for Hepatocellular Cancer: Ablation Therapies
- 9.1 Introduction
  - 9.1.1 Mechanisms and Instrumentation for RFA
  - 9.1.2 Pre-Procedure Requirements
  - 9.1.3 The Procedure
  - 9.1.4 Applicability
  - 9.1.5 Complications
  - 9.1.6 Follow-Up
  - 9.1.7 Results of RFA and Other Forms of Ablation Therapy
- Conclusion
- References
Minimally Invasive Therapies for Hepatocellular Cancer: Catheter-Directed Therapies
- 10.1 Introduction
  - 10.1.1 Transarterial Chemoembolization forHepatocellular Carcinoma
    - 10.1.1.1 Iodized Poppy Seed Oil
    - 10.1.1.2 Drug-Eluting Beads
  - 10.1.2 Indications for TACE
  - 10.1.3 Combination of RFA and TACE
  - 10.1.4 Chemoembolization and Portal Vein Embolization Prior to Surgical resection
  - 10.1.5 Sorafenib and DEB-TACE
- Conclusion
- References
Radiation Oncology in the Treatment of Hepatocellular Carcinoma
- 11.1 Introduction
  - 11.1.1 External Beam Radiotherapy in the Treatment of Hepatocellular Carcinoma
  - 11.1.2 Stereotactic Body Radiotherapy
  - 11.1.3 Radioembolization
- Conclusion
- References
Design of an IT System for Hepatocellular Carcinoma
- 12.1 Introduction
  - 12.1.1 ITS-PM: Organization and Architecture
    - 12.1.1.1 Requirements for an ITS-PM
  - 12.1.2 Clinical and Research Components
    - 12.1.2.1 Defining the Requirements of the ITS-PM
- Conclusion
- References
Outlook and Expert Recommendations for Predictive, Preventive and Personalized Medicine and Hepatocellular Carcinoma
- 13.1 Introduction
- 13.2 Building on the Barcelona Clinic Liver Cancer Staging System
  - 13.2.1 Enhanced Screening and “Shift to the Left”
  - 13.2.2 Possible Expanded Role of Targeted Therapies
  - 13.2.3 Improved Outcomes with Further Personalized Approach
- 13.3 New Algorithms
- Conclusion
- References
Index